We empower people with innovative treatment solutions


News & Insights

JULY 17, 2024
Orexo Q2 2024 Interim Report

JULY 16, 2024
Orexo shares new information on OX124, a high-dose naloxone rescue medication in development for opioid overdose

JULY 10, 2024
Orexo AB´s sustainability work ranked among top 5% by EcoVadis



A commercial stage pharmaceutical company with three revenue generating pharmaceutical products


AmorphOX® - a world-class powder-based drug delivery technology, leading to a new wave of a both small and large molecule pharmaceuticals.



Development pipeline targeting large medical needs

ESG sustainable investing

Read all documents related to the refinancing of the existing bond - MARCH 2024

Read more

Key financial figures

Group net revenue

615 MSEK
Last Twelve Months, Q323-Q224


Last Twelve Months, Q323-Q224

US Commercial segment EBIT

145 MSEK
Last Twelve Months, Q323-Q224

Cash position

140 MSEK
To read all NEWS go to Media in the top menu